SASAKI Yasushi

写真a

Affiliation

Medical Development Center Dean, Department of Liberal Arts and Sciences, Biology

Job title

Professor
To the head of this page.▲

Education 【 display / non-display 】

  • 　
    -
    1988

    Sapporo Medical University   School of Medicine   Department of Medicine  

To the head of this page.▲

Degree 【 display / non-display 】

  • Sapporo Medical University   MD, PhD (Medical Science)

To the head of this page.▲

Research Experience 【 display / non-display 】

  • 2018.01
    -
    Now

    Sapporo Medical University   Center for Medical Education   Professor

  • 2018.01
    -
    Now

    Sapporo Medical University   Graduate School of Medicine   Professor

  • 2008.06
    -
    2017.12

    Sapporo Medical University   School of Medicine   Associate Professor

  • 2004.04
    -
    2008.05

    Sapporo Medical University   School of Medicine   Assistant Professor

  • 1999.10
    -
    2004.03

    Sapporo Medical University   School of Medicine   Instructor

To the head of this page.▲

Professional Memberships 【 display / non-display 】

  • 2021.04
    -
    Now

    Japan Association for Medical Informatics

  • 2018.04
    -
    Now

    Japan Society for Medical Education

  • 2010.01
    -
    Now

    International Society of Oncology & BioMarkers (ISOBM)

  • 2009.01
    -
    Now

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

  • 2005.01
    -
    Now

    Japanese Society of Molecular Medicine

display all >>

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Life sciences   Genomics  

  • Life sciences   Tumor biology  

  • Life sciences   Gastroenterology  

To the head of this page.▲

Affiliation 【 display / non-display 】

  • Sapporo Medical University   Biology Division, Department of Liberal Arts and Sciences, Center for Medical Education   Professor  

To the head of this page.▲
 

Research Interests 【 display / non-display 】

  • Cancer-related genes

  • Cancer genetics

  • p53 family

  • Digestive cancer

  • p53

display all >>

To the head of this page.▲

Papers 【 display / non-display 】

  • Associations between serum insulin-like growth factor-related molecules and colorectal cancer risk by tumor location: a nested case-control study.

    Yasushi Adachi, Masanori Nojima, Yingsong Lin, Yasushi Sasaki, Hiro-O Yamano, Hiroshi Nakase, Kenji Wakai, Mitsuru Mori, Akiko Tamakoshi

    Digestion     1 - 19  2025.03  [Refereed]  [International journal]

    　View Summary

    Introduction, The activity of the mitogen insulin-like growth factor (IGF) is controlled by IGF-binding protein (IGFBP). Colorectal cancers (CRCs) are heterogeneous, with left- and right-sided CRC showing different clinical and molecular characteristics. This case-control study, nested in the Japan Collaborative Cohort study, assessed associations between serum levels of IGF-related molecules and incidences of CRC by location. Methods, A baseline survey obtained serum samples from 39,242 participants. Subjects diagnosed with CRC during follow-up were regarded as cases. Conditional logistic regression modeling was used to calculate odds ratios (ORs) for cancer incidence associated with IGF-related molecules. Results, This analysis included 176 cases and 524 controls. No IGF-related molecules appeared associated with risks of overall or left-sided CRC. Both total IGFBP3 and free IGFBP3 (estimated as IGFBP3-(IGF1+IGF2)) were associated with incidence of right-sided CRC (P-for-trends=0.027 and 0.003, respectively), with the third tertile of total and free IGFBP3 showing the highest risk (OR=6.25 and 7.96, respectively). Free IGF, estimated as (IGF1+IGF2)/IGFBP3, was inversely associated with incidence of right-sided CRC (P-for-trends=0.014), with the third tertile showing the lowest risk (OR=0.18). Among subjects followed for over 3 years, association of IGF-related molecules with overall CRC was similar. Free IGFBP3 was associated with incidence of right-sided CRC (P-for-trends=0.004). Free IGF was inversely associated with incidence of right-sided CRC (P-for-trends=0.002). However, free IGFs were associated with risk of left-sided CRC (P-for-trends=0.041), with the third tertile showing the highest risk (OR=3.10). Conclusions, Serum IGF-related molecules are associated with risk of CRC. These associations might differ by tumor location.

    DOI PubMed

  • Impact of Sensitive Circulating Tumor DNA Monitoring on CT Scan Intervals During Postoperative Colorectal Cancer Surveillance

    Tomoko Sasaki, Takeshi Iwaya, Mizunori Yaegashi, Masashi Idogawa, Hayato Hiraki, Masakazu Abe, Yuka Koizumi, Noriyuki Sasaki, Akiko Yashima-Abo, Ryosuke Fujisawa, Fumitaka Endo, Shoichiro Tange, Koki Otsuka, Akira Sasaki, Mari Masuda, Masashi Fujita, Hidewaki Nakagawa, Fumiaki Takahashi, Yasushi Sasaki, Takashi Tokino, Satoshi S. Nishizuka

    Annals of Surgery Open ( Ovid Technologies (Wolters Kluwer Health) )  6 ( 1 ) e549 - e549  2025.02  [Refereed]

    　View Summary

    Objective: This study investigated whether digital polymerase chain reaction (dPCR)-based circulating tumor DNA (ctDNA) monitoring can allow longer intervals between computed tomography (CT) scans during postoperative surveillance of colorectal cancer (CRC). Background: Practical guidelines still recommend intensive postoperative surveillance of CRC using periodical CT scans and serum carcinoembryonic antigen testing. Methods: The longitudinal dynamics of ctDNA for 52 patients with CRC as measured by dPCR using probes targeting 87 individual tumor-specific mutations (1–5 per patient) were compared with results from conventional (ie, clinical) surveillance using serum tumor markers and CT. Results: A total of 382 CT procedures were carried out for the patient cohort (3.3/year per patient) and the median lead time from ctDNA relapse to clinical relapse was 182 days (range, 0–376 days). If the CT interval was annual, potential delays in the detection of clinical relapse would have occurred for 7 of the 10 patients who experienced clinical relapse (9 of 13 events), with a median delay of 164 days (range, 0–267 days). If annual CT surveillance was performed together with ctDNA monitoring, 218 (57.1%) CTs would not have been needed to detect the first clinical relapse. In addition, the ctDNA monitoring would have provided a lead time of 339 days for detection of clinical relapse (range, 42–533 days). Conclusions: Our findings suggest that the ctDNA monitoring as part of postoperative surveillance and clinical relapse detection for patients with CRC could allow the CT interval to be lengthened. Trial Registration: This trial was registered with University Hospital Medical Information Network Clinical Trial Registry (UMIN000045114).

    DOI

  • Targeted dynamic phospho-proteogenomic analysis of gastric cancer cells suggests host immunity provides survival benefit.

    Kohei Kume, Midori Iida, Takeshi Iwaya, Akiko Yashima-Abo, Yuka Koizumi, Akari Endo, Kaitlin Wade, Hayato Hiraki, Valerie Calvert, Julia Wulfkuhle, Virginia Espina, Doris R Siwak, Yiling Lu, Kazuhiro Takemoto, Yutaka Suzuki, Yasushi Sasaki, Takashi Tokino, Emanuel Petricoin 3rd, Lance A Liotta, Gordon B Mills, Satoshi S Nishizuka

    Molecular & cellular proteomics : MCP     100870 - 100870  2024.10  [Refereed]  [International journal]

    　View Summary

    Despite of massive emergence of molecular targeting drugs, the mainstay of advanced gastric cancer (GC) therapy is DNA-damaging drugs. Using a reverse-phase protein array-based proteogenomic analysis of a panel of eight GC cell lines, we identified genetic alterations and signaling pathways, potentially associated with resistance to DNA-damaging drugs, including 5-fluorouracil (5FU), cisplatin, and etoposide. Resistance to cisplatin and etoposide, but not 5FU, was negatively associated with global copy number loss, vimentin expression, and caspase activity, which are considered hallmarks of previously established EMT subtype. The segregation of 19,392 protein expression time courses by sensitive and resistant cell lines for the drugs tested revealed that 5FU-resistant cell lines had lower changes in global protein dynamics, suggesting their robust protein level regulation, compared to their sensitive counterparts, whereas the cell lines that are resistant to other drugs showed increased protein dynamics in response to each drug. Despite faint global protein dynamics, 5FU-resistant cell lines showed increased STAT1 phosphorylation and PD-L1 expression in response to 5FU. In publicly available cohort data, expression of STAT1 and NFκB target genes induced by proinflammatory cytokines was associated with prolonged survival in GC. In our validation cohort, total lymphocyte count (TLC), rather than PD-L1 positivity, predicted a better relapse-free survival rate in GC patients with 5FU-based adjuvant chemotherapy than those with surgery alone. Moreover, TLC+ patients who had no survival benefit from adjuvant chemotherapy were discriminated by expression of IκBα, a potent negative regulator of NFκB. Collectively, our results suggest that 5FU resistance observed in cell lines may be overcome by host immunity or by combination therapy with immune checkpoint blockade.

    DOI PubMed

  • Synchronous cancers of the stomach and esophagus in a patient with autoimmune gastritis and pernicious anemia: a case report and review of the literature.

    Toshiyuki Kubo, Yasushi Adachi, Yasushi Sasaki, Yasuyo Adachi, Yukinari Yoshida, Takao Endo, Yoshifumi Ishii, Hiroaki Takahashi, Akira Goto

    International cancer conference journal   13 ( 4 ) 367 - 373  2024.10  [Refereed]  [International journal]

    　View Summary

    Type-A gastritis/autoimmune gastritis (AIG) has gained renewed attention due to declining Helicobacter pylori infection rates and increasing eradication. AIG is associated with pernicious anemia (PA) and is prone to complicate various tumors, such as gastric cancer and neuroendocrine tumors. This report describes a case of AIG with PA in which gastric and esophageal cancers arose simultaneously. An 86-year-old woman had been diagnosed with PA and AIG 9 years earlier. As routine blood tests revealed high levels of carcinoembryonic antigen, she underwent esophagogastroduodenoscopy, which revealed a type 0-IIa lesion in the middle part of the stomach and a type 0-IIa + IIb lesion in the lower esophagus. Endoscopic submucosal dissection was performed on both lesions, since neither distant nor lymph node metastases were identified. Histological examination showed gastric tubular adenocarcinoma and esophageal squamous cell carcinoma. Immunohistology revealed that cells from neither cancer expressed gastrin, gastrin receptor, or p53. Whole-exome sequencing showed 8 gene mutations in the esophageal cancer and 6 mutations in 5 genes in the gastric cancer. The reason for the lack of p53 immunostaining was that TP53 was mutated in these cancers, although TP53 mutations differed. Thus, TP53 mutations may not be detected by immunostaining alone. When treating patients with AIG/PA, clinicians must be aware of the possibility of esophageal cancer coexisting with gastric cancer.

    DOI PubMed

  • 口腔がんにおける悪性化関連遺伝子群転写抑制機構の解明(Nuclear protein X represses the transcription of malignancy-related genes in oral cancer cell lines)

    丹下 正一朗, 後藤 生子, 川島 秀器, 井戸川 雅史, 佐々木 泰史, 時野 隆至

    日本癌学会総会記事 ( (一社)日本癌学会 )  83回   P - 2241  2024.09

display all >>

To the head of this page.▲

Books and Other Publications 【 display / non-display 】

  • 分子標的療法の基礎と臨床

    佐々木 泰史, 時野 隆至( Part： Contributor, p53, p63, p73の機能とp53ファミリーを標的としたがん療法への応用)

    篠原出版新社  2005

  • 内科疾患クリニカルガイド 消化器・免疫・血液・代謝疾患

    佐々木 泰史( Part： Contributor, 癌性疼痛治療の実際)

    中山書店  1999

  • 日本臨床別冊巻 肝・胆道系症候群 肝臓編（上巻）

    佐々木泰史, 坂本裕史, 日野田裕治, 矢花剛( Part： Joint author, 肝粘表皮癌、肝内胆管粘表皮癌)

    日本臨床社  1995.04

  • 血液学

    今井浩三, 佐々木泰史, 辻崎正幸( Part： Contributor, 原発性マクログロブリン血症)

    中外医学社  1991

  • Therapeutic plasmapheresis VIII

    Suga M, Tsuchida M, Arimura Y, Matsuno K, Sasaki Y, Miyachi T, Ishida S, Yachi A( Part： Contributor, Basic and clinical evaluation of anion exchange resin column for treatment of jaundice)

    ISAO Press  1989

To the head of this page.▲

Misc 【 display / non-display 】

  • 胃底線ポリポーシスを背景とした胃腺窩上皮癌

    足立 靖, 見田 裕章, 岩田 徳和, 佐々木 泰史, 安達 靖代, 吉田 幸成, 遠藤 高夫, 石井 良文, 後藤 啓

    日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  62回   P29 - 6  2024.10

  • 内視鏡的切除により診断できた皮膚様食道扁平上皮癌

    足立 靖, 菊地 剛史, 後藤 啓, 吉田 幸成, 石井 良文, 高橋 宏明, 佐々木 泰史, 仲瀬 裕志, 遠藤 高夫

    日本消化管学会雑誌 ( (一社)日本消化管学会 )  8 ( Suppl. ) 360 - 360  2024.01

  • RAS野生型進行大腸癌に対する抗EGFR抗体治療におけるDroplet Digital PCRを用いた血中循環腫瘍DNAのモニタリング前向き観察研究

    高橋直樹, 中村慶史, 木藤陽介, 久保田英嗣, 朝山雅子, 粂川陽祐, 原浩樹, 松島知広, 辻国広, 片岡洋望, 津矢田明泰, 佐々木泰史, 井戸川雅史, 時野隆至, 澤田武

    大腸癌研究会プログラム・抄録集   101st  2024

    J-GLOBAL

  • Liver metastasis recurrence of gastric adenocarcinoma mixed with neuroendocrine cancer

    足立靖, 足立靖, 見田裕章, 佐々木泰史, 吉田幸成, 遠藤高夫, 石井良文, 西田靖仙, 奥田博介, 高橋宏明, 後藤啓

    日本がん転移学会学術集会・総会プログラム抄録集   33rd  2024

    J-GLOBAL

  • 症例報告からPrecision Medicineへ-第1部- 悪性貧血を伴う自己免疫性胃炎における胃癌と食道癌の同時発生(Simultaneous cancers of the stomach and esophagus in autoimmune gastritis with pernicious anemia)

    足立 靖, 久保 俊之, 佐々木 泰史, 安達 靖代, 吉田 幸成, 遠藤 高夫, 石井 良文, 高橋 宏明, 後藤 啓

    日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  61回   ICCJ1 - 3  2023.10

display all >>

To the head of this page.▲

Industrial Property Rights 【 display / non-display 】

To the head of this page.▲

Other 【 display / non-display 】

  • 緩和ケア研修会修了（北-4252号）

    2017.05
    　
    　

  • General Clinical Oncologist (Japanese Board of Cancer Therapy)（No. 09100061）

    2010.04
    -
    Now

  • 日本癌治療学会臨床試験登録医 （0985号）

    2004.08
    -
    Now

  • Board Certified Hepatologist of the Japan Society of Hepatology（No. 3150）

    1999.04
    -
    Now

  • Board Certified Fellow of the Japan Gastroenterological Endoscopy Society（No. 0094005）

    1994.12
    -
    Now

display all >>

To the head of this page.▲

Awards 【 display / non-display 】

  • 北海道医師会賞

    2021.10  

    Winner： Yasushi Sasaki

  • 北海道知事賞

    2021.10   がん抑制遺伝子p53とそのファミリー (p73、p63)の機能解明

    Winner： Yasushi Sasaki

  • 第14回日本消化器関連学会週間優秀演題賞

    2006.12   日本消化器関連学会週間  

    Winner： Yasushi Sasaki

  • 第44回日本癌治療学会総会優秀演題賞

    2006.10   日本癌治療学会総会  

    Winner： Yasushi Sasaki

  • 札幌医科大学医師会学術賞

    2003.03   札幌医科大学医師会  

    Winner： Yasushi Sasaki

To the head of this page.▲

Research Projects 【 display / non-display 】

  • p53ネットワーク破綻による翻訳動態の変化と発がん過程における意義

    2024( 56th ) Research Grants of Princess Takamatsu Cancer Research Fund

    Project Year :

    2025.03
    　
    　
     

    Yasushi Sasaki

    Authorship： Principal investigator

  • Development of molecular targeted therapy for primary central nervous system lymphomas based on genome and metabolome data.

    Grant-in-Aid for Scientific Research (B)

    Project Year :

    2024.04
    -
    2026.03
     

    山中 龍也, 高島 康郎, 川口 淳, 佐々木 泰史, 深井 順也

  • p53の機能獲得変異に関わる小型タンパク質の探索と機能解明

    日本イーライリリー イノベーション研究助成

    Project Year :

    2023.12
    -
    2025.03
     

    佐々木泰史

    Authorship： Principal investigator

  • p53ネットワークに関わるマイクロプロテインの探索と食道扁平上皮癌新規治療戦略

    科学研究費助成事業 基盤研究(C)

    Project Year :

    2023.04
    -
    2026.03
     

    佐々木 泰史

    Authorship： Principal investigator

  • 非乳頭部十二指腸腺癌の2つの独立した発癌経路の検証とその分子機構の解明

    金沢大学がん進展制御研究所共同研究（一般研究、新規）

    Project Year :

    2023.04
    -
    2024.03
     

    佐々木泰史, 澤田 武, 中村 慶史, 源 利成

    Authorship： Principal investigator

display all >>

To the head of this page.▲
 

Committee Memberships 【 display / non-display 】

  • 2022.04
    -
    Now

      Councilor, The Japanese Electrophoresis Society

  • 2012.01
    -
    Now

      Councilor, The Japan Society of Drug Delivery System

  • 2011.01
    -
    Now

      Councilor, Japanese Society of Molecular Medicine

  • 2010.01
    -
    Now

      Councilor, The Japanese Cancer Association

  • 2005.01
    -
    Now

      Councilor, Japanese Society of Gastroenterology

display all >>

To the head of this page.▲

Social Activities 【 display / non-display 】

  • Advisor, Sapporo Medical University Golf Club

    2014.04
    -
    Now

To the head of this page.▲

Academic Activities 【 display / non-display 】

  • Translational Oncology: International Advisory Review Board

    Peer review

    2021
    -
    Now

  • Cancer Treatment and Research Communications: Editorial Board

    Peer review

    2021
    -
    Now

  • Gastroenterology Insights: Editorial Board

    Peer review

    2019
    -
    Now

  • Molecular Medicine Reports: Editorial Board

    Peer review

    2018
    -
    Now
To the head of this page.▲